CLINICAL TRIALS PROFILE FOR GONADORELIN HYDROCHLORIDE

All Clinical Trials for Gonadorelin Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01907009 ↗	A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).	Unknown status	Barts & The London NHS Trust	Phase 2/Phase 3	2013-01-01	The management of (castration-resistant) prostate cancer (CRPC) is becoming increasingly complex. The use of peripheral anti-androgens with gonadorelin analogues (maximum androgen blockade) is common place. Following the failure of such an approach, several strategies may be employed. Both corticosteroids and estrogens have a role and increasingly chemotherapy is being used. The demonstration of enhanced survival using 3 weekly docetaxel has meant that this is viewed by many as the standard of care for fit patients. Melphalan is an established alkylating drug that has demonstrated some activity in CRPC, but to date, myelosuppression has prevented adequate dosing. We have recently conducted a phase I dose escalation study using melphalan and whole blood stem cell re-infusion and it shows that median overall survival is 22 months, which is higher than the median survival rate of 19 months for Docetaxel Data from a previous phase I study has proved the successful administration of higher doses of IV Melphalan in combination with autologous blood infusion in patients with Castration-resistant prostate cancer. Rapid falls in circulating tumour cells were seen within 2 weeks of starting Melphalan, however slow platelet recovery meant longer periods of platelet transfusion. For this study we intend to assess the efficacy of an intensified intravenous melphalan with autologous whole blood stem cell transplantation over three treatment cycles. 39 patients will be enrolled over a 3 year period and at least 17 patients need to survive progression free at least 6-months for this study to be considered positive. Mel-CAP is a combination chemotherapy consisting of two chemotherapy drugs: MELPHALAN and LENOGRASTIM for 3 cycles alternately.
NCT02349347 ↗	A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).	Unknown status	Barts & The London NHS Trust	Phase 2/Phase 3	2013-01-01	The management of (castration-resistant) prostate cancer (CRPC) is becoming increasingly complex. The use of peripheral anti-androgens with gonadorelin analogues (maximum androgen blockade) is common place. Following the failure of such an approach, several strategies may be employed. Both corticosteroids and estrogens have a role and increasingly chemotherapy is being used. The demonstration of enhanced survival using 3 weekly docetaxel has meant that this is viewed by many as the standard of care for fit patients. Melphalan is an established alkylating drug that has demonstrated some activity in CRPC, but to date, myelosuppression has prevented adequate dosing. We have recently conducted a phase I dose escalation study using melphalan and whole blood stem cell re-infusion and it shows that median overall survival is 22 months, which is higher than the median survival rate of 19 months for Docetaxel Data from a previous phase I study has proved the successful administration of higher doses of IV Melphalan in combination with autologous blood infusion in patients with Castration-resistant prostate cancer. Rapid falls in circulating tumour cells were seen within 2 weeks of starting Melphalan, however slow platelet recovery meant longer periods of platelet transfusion. For this study we intend to assess the efficacy of an intensified intravenous melphalan with autologous whole blood stem cell transplantation over three treatment cycles. 39 patients will be enrolled over a 3 year period and at least 17 patients need to survive progression free at least 6-months for this study to be considered positive. Mel-CAP is a combination chemotherapy consisting of two chemotherapy drugs: MELPHALAN and LENOGRASTIM for 3 cycles alternately.
NCT02349347 ↗	A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).	Unknown status	Queen Mary University of London	Phase 2/Phase 3	2013-01-01	The management of (castration-resistant) prostate cancer (CRPC) is becoming increasingly complex. The use of peripheral anti-androgens with gonadorelin analogues (maximum androgen blockade) is common place. Following the failure of such an approach, several strategies may be employed. Both corticosteroids and estrogens have a role and increasingly chemotherapy is being used. The demonstration of enhanced survival using 3 weekly docetaxel has meant that this is viewed by many as the standard of care for fit patients. Melphalan is an established alkylating drug that has demonstrated some activity in CRPC, but to date, myelosuppression has prevented adequate dosing. We have recently conducted a phase I dose escalation study using melphalan and whole blood stem cell re-infusion and it shows that median overall survival is 22 months, which is higher than the median survival rate of 19 months for Docetaxel Data from a previous phase I study has proved the successful administration of higher doses of IV Melphalan in combination with autologous blood infusion in patients with Castration-resistant prostate cancer. Rapid falls in circulating tumour cells were seen within 2 weeks of starting Melphalan, however slow platelet recovery meant longer periods of platelet transfusion. For this study we intend to assess the efficacy of an intensified intravenous melphalan with autologous whole blood stem cell transplantation over three treatment cycles. 39 patients will be enrolled over a 3 year period and at least 17 patients need to survive progression free at least 6-months for this study to be considered positive. Mel-CAP is a combination chemotherapy consisting of two chemotherapy drugs: MELPHALAN and LENOGRASTIM for 3 cycles alternately.
NCT02705014 ↗	Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome	Unknown status	Peking Union Medical College Hospital	N/A	2016-01-01	To investigate the hormone response of hypothalamic-pituitary-gonad axis and spermatogenesis in male pituitary stalk interruption syndrome patients by pulsatile GnRH therapy.

Clinical Trial Conditions for Gonadorelin Hydrochloride

Condition Name

Condition Name for Gonadorelin Hydrochloride
Intervention	Trials
Sleep Restriction	2
Castrate Resistant Prostate Cancer	2
Hypogonadotropic Hypogonadism	2
Stage IIC Prostate Cancer AJCC v8	1

Condition MeSH

Condition MeSH for Gonadorelin Hydrochloride
Intervention	Trials
Prostatic Neoplasms	3
Hypogonadism	2
Infertility	2
Obesity	1

Clinical Trial Locations for Gonadorelin Hydrochloride

Trials by Country

Trials by Country for Gonadorelin Hydrochloride
Location	Trials
United States	23
China	3
United Kingdom	2

Trials by US State

Trials by US State for Gonadorelin Hydrochloride
Location	Trials
California	3
Mississippi	1
Michigan	1
Maryland	1
Kansas	1

Clinical Trial Progress for Gonadorelin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Gonadorelin Hydrochloride
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Gonadorelin Hydrochloride
Clinical Trial Phase	Trials
RECRUITING	3
Unknown status	3
Active, not recruiting	2

Clinical Trial Sponsors for Gonadorelin Hydrochloride

Sponsor Name

Sponsor Name for Gonadorelin Hydrochloride
Sponsor	Trials
Barts & The London NHS Trust	2
Los Angeles Biomedical Research Institute	2
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	2

Sponsor Type

Sponsor Type for Gonadorelin Hydrochloride
Sponsor	Trials
Other	13
NIH	1

Gonadorelin Hydrochloride Market Analysis and Financial Projection

Last updated: April 28, 2026

Gonadorelin Hydrochloride: Clinical Trials Update and Market Outlook (2019–2026)

What is the current clinical-trials status for gonadorelin hydrochloride?

Gonadorelin hydrochloride (a GnRH agonist) remains a mature, off-patent endocrine therapy in most jurisdictions. As of the latest publicly indexed sources available through 2024, the clinical-trials footprint is dominated by small, non-registration studies rather than late-stage, confirmatory programs.

Trial activity profile (high-level)

• Phase 1–2: Intermittent studies in reproductive endocrinology and hypothalamic-pituitary axis assessment, typically evaluating pharmacodynamics and pituitary response measures rather than new efficacy endpoints.
• Phase 3/registrational: No widely indexed, clearly active Phase 3 program that would reasonably support a modern regulatory resubmission or new label expansion based on pivotal data.
• Regulatory intent: Most contemporary work centers on comparative formulations, diagnostic protocol optimization, or disease-area case cohorts rather than new global prescribing indications.

Key operational implication

• The most investable clinical path for gonadorelin at this stage is typically product lifecycle management (formulation, route, dosing convenience, stability) and niche clinical differentiation, not de novo large Phase 3 development.

Bottom line

• Current publicly indexed activity supports that gonadorelin is still used in clinical practice and continues to generate academic and small-company exploratory data, but it does not show the kind of late-stage density that would indicate a near-term, registration-grade turnaround.

---

Where does gonadorelin sit in the competitive landscape?

Gonadorelin is used in reproductive endocrinology for specific clinical workflows (including stimulation testing and selected therapeutic use-cases). Competitive pressure is structurally different from oncology or immunology:

• Direct competitors: Other GnRH products, including gonadorelin analogs and alternative stimulation regimens, depending on country practice.
• Substitution pressure: Many settings use protocol-based pituitary testing and stimulation paradigms where the product is one component of a larger diagnostic pathway.
• Treatment ecosystem: In disorders like hypogonadotropic hypogonadism, clinicians often consider broader endocrine regimens (e.g., gonadotropins and other hormonal therapies), which can dilute absolute demand for gonadorelin.

Therapeutic durability

• The drug’s market position is driven by clinical utility in established pathways, not by a rapidly evolving mechanism-of-action race.

---

What is the market reality for gonadorelin hydrochloride?

Gonadorelin hydrochloride is an older active ingredient with a mature generic landscape. Market value tends to track:

1. Endocrinology clinic volumes
2. Diagnostic testing frequency
3. Availability and pricing across generic and branded product sets
4. Hospital formulary decisions and tender cycles

Because the product is widely available, pricing is typically constrained by generics, and unit economics depend heavily on procurement channel and regional distribution rather than premium differentiation.

---

Market sizing constraints: what can be projected with high confidence?

A precise global dollar market size for gonadorelin hydrochloride is not reliably extractable from public sources in a way that supports investment-grade conclusions without proprietary dataset access. However, for projections, a business-actionable approach is to model volume and pricing dynamics:

Projection framework

• Volume trend: Stable to low growth driven by ongoing diagnostic and clinical use, offset by substitution and tighter diagnostic protocols.
• Price trend: Gradual erosion in many markets due to generics and tender pressure; occasional stabilization where supply is constrained or where proprietary formulation remains.

Time horizon

• 2025–2026: Stable market with modest growth where endocrine testing demand remains steady and generic supply stays consistent.
• 2027–2030: Low-to-flat growth profile unless a major label expansion, formulation shift, or guideline change increases utilization.

---

How do clinical and regulatory dynamics affect market projections?

Because gonadorelin is mature, near-term value drivers come from operational shifts rather than new clinical breakthroughs:

Upward drivers

• Expanded use in specialized endocrine testing workflows.
• New or improved formulations that reduce administration burden.
• Better supply continuity and tender wins with stable unit pricing.

Downward drivers

• Substitution by alternative diagnostic protocols or analogs where clinically acceptable.
• Formularies shifting toward bundled endocrine testing regimens.
• Continued generic price pressure in mature markets.

---

Market projection (scenario-based, operational not hypothetical)

Given the mature, off-patent status and absence of clearly indexed Phase 3 registrational momentum, the most defensible projection is a low-growth, price-constrained trajectory.

Base-case projection (qualitative)

• 2025–2026: Low single-digit growth in units, with flat-to-declining price in generic-heavy regions.
• 2027–2030: Low single-digit growth in units, with more pronounced price compression where tenders reset.

Investment interpretation

• The commercial playbook is distribution and formulary execution rather than clinical risk underwriting typical of late-stage development.

---

What are the most likely differentiating moves for the next cycle?

Without relying on registrational late-stage innovation, the next cycle for gonadorelin typically clusters into four practical levers:

1. Route optimization: Improving usability for endocrine testing workflows.
2. Stability and shelf-life: Reducing wastage in hospitals.
3. Dosing convenience: Simplifying protocols for clinic and diagnostic labs.
4. Regional supply strategy: Ensuring reliable availability during tender periods.

These moves affect market share more reliably than new efficacy claims in a mature competitive setting.

---

Key Takeaways

• Gonadorelin hydrochloride is a mature endocrine therapy with a clinical-trials footprint dominated by smaller studies rather than new Phase 3 registrational programs.
• The market behaves as a generic-constrained, workflow-driven product, where unit demand depends on endocrine testing and pricing depends on tender dynamics.
• Base-case outlook is stable to low growth through 2026, with flat-to-down pricing in most markets.
• The highest-probability differentiation is operational (formulation, stability, supply execution), not breakthrough clinical development.

---

FAQs

1. Is gonadorelin hydrochloride currently being developed for new indications in Phase 3?
   Publicly indexed activity does not show a clear, registration-grade Phase 3 pipeline that would indicate near-term label expansion.

2. What typically drives demand for gonadorelin hydrochloride in mature markets?
   Endocrine clinic volume and diagnostic stimulation testing protocols.

3. How does generic competition affect pricing?
   Tender cycles and generic supply usually drive flat-to-declining pricing over time, limiting revenue growth to volume and market-share gains.

4. What type of product strategy has the highest chance of improving market performance?
   Formulation and lifecycle execution (stability, shelf-life, ease of use) plus reliable procurement and tender performance.

5. What is the most realistic growth profile for 2025–2030?
   Low single-digit unit growth with price compression, resulting in a low-growth market unless clinical workflows change.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Search results for “gonadorelin hydrochloride”. https://clinicaltrials.gov/
[2] FDA. Drug Approval and Databases (access to labeling and historical regulatory context for gonadorelin-related products where applicable). https://www.fda.gov/drugs/drug-approvals-and-databases
[3] EMA. European Medicines Agency: database search for gonadorelin-containing products and related EPAR/assessment entries where available. https://www.ema.europa.eu/